New technology identifies potential drugs to fight resistant strains

Credit: Unsplash / CC0 public domain

Researchers at the University of Miami, Ohio, have optimized new technology that allows scientists to assess how potential inhibitors work against antibiotic-resistant strains. This technique, called native mass spectrometry, allows scientists to quickly identify the best candidates for effective clinical drugs, especially when bacteria can no longer be treated with antibiotics alone. The study will be presented at the American Society of Microbiology’s World Microbiology Forum online conference on June 21, 2021.

Misuse of antibiotics in the last century Bacterial resistance, Leads to many bacterial infections that can no longer be treated with current antibiotics. 2.8 Million People Are Diagnosed Each Year In The United States Bacterial Infection It is resistant to one or more antibiotics, and according to the US Centers for Disease Control and Prevention, resistant infections have killed 35,000 people.

“One way to fight antibiotic resistance is to use combination drug / inhibitor therapies,” said PhD Kaitlin Thomas. Presents chemistry candidates and research authors. An example of this type of treatment is Augmentin, a prescription antibiotic used to treat bacterial infections of the respiratory tract, which consists of the antibiotic amoxicillin and the inhibitor of clavulanic acid. Clavulanic acid inactivates an important protein used by bacteria to become resistant to amoxicillin. When a bacterial protein is inactivated, the antibiotic amoxicillin is left to kill the bacteria, thus treating the infection.

Before using new inhibitors in the clinic, scientists need to fully understand how inhibitors work. In the current study, Thomas and his team studied a bacterial protein called metallobeta-lactamase. This makes many clinical strains of bacteria resistant to all penicillin-type antibiotics. Like penicillin antibiotics, it accounts for over 60% of all antibiotic weapons available for the treatment of bacterial infections.

Many laboratories around the world are trying to create new inhibitors that inactivate metallobeta-lactamase, but Thomas and his colleagues are instead analyzing how these new inhibitors work. I am. “Because metallobeta-lactamase contains two metal ions. You can study them using various spectroscopic techniques. These experiments provide a better understanding of the behavior of inhibitors and whether they may be candidates for future clinical use. “

Hundreds of potential inhibitors have been reported in the literature and several patents have been filed for metallo-beta-lactamase inhibitors. Some of the reported inhibitors work by removing the necessary components of metallobeta-lactamase. These same inhibitors can remove this same necessary component from other human proteins and cause serious side effects. Other inhibitors bind directly to metallobeta-lactamase and inactivate proteins. This type of inhibitor is ideal for new inhibitors that can be used clinically.

Fighting Antibiotic-Resistant Bacteria Has Brilliant New Weapons

For more information:

Provided by
American Society for Microbiology

Quote: Resistant bacteria acquired on June 20, 2021 from by new technology (June 20, 2021)) Can be identified as a drug who can fight

This document is subject to copyright. No part may be reproduced without written permission except for fair trade purposes for personal investigation or research. The content is provided for informational purposes only.

New technology identifies potential drugs to fight resistant strains

Source link New technology identifies potential drugs to fight resistant strains

Source link

About Tiffany Wright

Check Also

Simplifeye Expands Technology Suite for Retail Healthcare Practices

NEW YORK, July 20, 2021 / PRNewswire / – Simplifeye, a technology platform improving patient …

Leave a Reply

Your email address will not be published. Required fields are marked *